Skip to main content
. 2017 Jul 27;8(49):85214–85223. doi: 10.18632/oncotarget.19620

Figure 2. Efficacy of 3C23K in OC PDX models and Z3 xenografts.

Figure 2

(A) Percent change in tumor cross-sectional area over time in MISIIR-H (top) and MISIIR-L (bottom) OC PDX models as determined by ultrasound twice weekly. (B) Change in disease burden score in Z3 xenografts during efficacy studies. Values reported as percent change at each day of treatment as compared to the beginning of treatment, or day 0.